Figure 2From: FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients Primary efficacy analysis: Response Evaluation Criteria in Solid Tumors (RECIST) tumor response rates (complete response + partial response) at month 6, based on the central review (modified intention to treat, last observation carried forward). Back to article page